PolyPhil Next

€ 95.00

(3.5 stars) • 10 reviews

Croma PolyPhil Next is a next-generation intradermal injectable gel formulated with polynucleotides and hyaluronic acid. Developed using innovative biotechnological processes, this product offers dual-action skin revitalization: deep regeneration through highly purified polynucleotides and intense hydration via hyaluronic acid.

In stock – delivered within 1–3 business days

Interested in bulk orders? Contact us at contact@toxify.shop
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.

Category

Polynucleotides

Brand

Croma

Manufacturer

Mastelli S.r.l.

SKU

CROMA-POLYPHIL-NEXT-2ML

Volumen

2ml (1x2ml)

Product Specifications:

Concentration

  • Polynucleotides
  • Hyaluronic Acid (concentration not disclosed on packaging)
  • Aqua (Water)
  • Additional excipients: Not fully listed on outer packaging

Indication

  • Biorevitalization and restructuring of skin showing signs of aging
  • Improving hydration, elasticity, and dermal density
  • Suitable for use on face, neck, décolleté, and hands
  • Ideal as supportive care post-laser, peelings, or other aesthetic treatments
  • Recommended for skin with visible dehydration, fine lines, and loss of tone

Contents of the set

  • 1 prefilled sterile syringe × 2 ml

Effect Duration

Initial visible effects within 1-2 weeks. Long-lasting hydration and dermal stimulation lasting up to 4-6 months. Can be used in treatment cycles for sustained improvement.

Brand

PolyPhil Next is part of the Croma PolyPhil range, which integrates regenerative biotechnology with aesthetic dermatology to offer advanced skin support solutions with polynucleotide-based injectables.

Manufacturer

Although branded by Croma Aesthetics, the product is manufactured by Mastelli S.r.l., a leading Italian biotechnology company based in Sanremo, Italy. Mastelli specializes in the development of regenerative medical solutions using purified polynucleotides, recognized for their high-quality standards and extensive research backing.